The global clinical trials activity saw a decrease of 12.2% in Q3 2022, when compared with the rolling average of the last four quarters (Q3 2021 to Q2 2022), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 51.8% share in Q3 2022, marking an increase of 1.2% in the total share when compared with the four-quarter average.
Go deeper with GlobalData
Non-industry sponsored trials accounted for a 48.2% share of all the clinical trials globally in Q2 2022, marking a decrease of 1.2% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q3 2022
See Also:
Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2022, accounting for a 28.9% share of all trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis was followed by the following therapy areas: Central Nervous System with a 13.9% share, Infectious Disease with a 13.6% share, Metabolic Disorders with an 8.5% share and Gastrointestinal with a 6.7% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.3% share, followed by Infectious Disease with a 15.7% share, Central Nervous System with a 14.6% share, Metabolic Disorders with an 8.3% share, and Cardiovascular with an 8.2% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q3 2022 | Activity |
| Oncology | 27.3% | 28.9% |  |
| Central Nervous System | 14.6% | 13.9% |  |
| Infectious Disease | 15.7% | 13.6% | |
| Metabolic Disorders | 8.3% | 8.5% | |
| Gastrointestinal | 7.0% | 6.7% | |
| Cardiovascular | 8.2% | 6.6% | |
| Dermatology | 5.0% | 5.5% | |
| Respiratory | 5.9% | 4.9% | |
| Immunology | 5.6% | 4.4% | |
| Musculoskeletal Disorders | 4.1% | 3.8% | |
| Hematological Disorders | 2.9% | 3.1% | |
| Ophthalmology | 2.9% | 3.0% | |
| Women’s Health | 1.9% | 2.4% | |
| Genito Urinary System And Sex Hormones | 2.8% | 2.3% | |
| Genetic Disorders | 1.8% | 1.9% | |
| Ear Nose Throat Disorders | 1.7% | 1.2% | |
| Male Health | 1.0% | 0.6% | |
| Mouth and Dental Disorders | 0.5% | 0.6% | |
| Hormonal Disorders | 0.8% | 0.5% | |
| Non Malignant Disorders | 0.3% | 0.4% | |
| Nutritional Disorders | 0.3% | 0.2% | |
Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q3 2022, accounting for a 26.2% share of all trials.
This was followed by the following therapy areas: Oncology with a 25.8% share, Cardiovascular with a 9.7% share, Infectious Disease with a 9.5% share, and Gastrointestinal with a 6.5% share.
In the last four quarters, Central Nervous System System held a lead over others for non-industry sponsored clinical trials with an average share of 25.5%, followed by Oncology with a 23.4% share, Infectious Disease with a 12.5% share, Cardiovascular with an 8.9% share, and Gastrointestinal with a 6.4% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q3 2022 | Activity |
| Central Nervous System | 25.5% | 26.2% | |
| Oncology | 23.4% | 25.8% | |
| Cardiovascular | 8.9% | 9.7% | |
| Infectious Disease | 12.5% | 9.5% | |
| Gastrointestinal | 6.4% | 6.5% | |
| Metabolic Disorders | 5.4% | 6.5% | |
| Musculoskeletal Disorders | 5.3% | 5.4% | |
| Dermatology | 2.6% | 3.7% | |
| Respiratory | 4.0% | 3.7% | |
| Women’s Health | 4.5% | 3.6% | |
| Genito Urinary System And Sex Hormones | 2.8% | 3.4% | |
| Hematological Disorders | 3.0% | 2.9% | |
| Immunology | 3.0% | 2.9% | |
| Mouth and Dental Disorders | 2.6% | 2.9% | |
| Ophthalmology | 2.0% | 2.2% | |
| Genetic Disorders | 0.6% | 1.3% | |
| Ear Nose Throat Disorders | 1.1% | 0.8% | |
| Nutritional Disorders | 0.7% | 0.8% | |
| Hormonal Disorders | 0.8% | 0.7% | |
| Male Health | 0.7% | 0.6% | |
| Non Malignant Disorders | 0.3% | 0.4% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q3 2022
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q3 2022 with a 54.3% share, compared to 57.0% in the last four quarters.
North America stood at second place with a 32.3% share in Q3 2022, over 28.5% in the last four quarters, followed by Europe with a 25.6% share in Q3 2022, as against 26.5% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 85.6% share in industry sponsored clinical trials in Q3 2022 when compared with 86.0% of average recorded in the last four quarters. Multinational trials accounted for a 14.4% share in Q3 2022, as against the four-quarter average of 14.1%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q3 2022 with a 58.9% share, over 55.3% in the last four quarters.
North America held the second position with a 22.5% share in Q3 2022, over 15.5% in the last four quarters, followed by Europe with a 13.3% share in Q3 2022, as against 13.4% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.8% share for non-industry sponsored clinical trials in Q3 2022, compared to 99.0% in the last four quarters. Multinational trials accounted for a 1.2% share in Q3 2022, as against 1.0% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q3 2022
Phase I trials outnumbered all other studies with a 36.2% share for industry sponsored trials in Q3 2022, compared to 40.1% average in the last four quarters.
The share of Phase II trials stood at 35.8% in Q3 2022, as against the four-quarter average of 33.5%. Phase III trials held a 17.1% share in Q3 2022, registering an increase of 1.8% over the last four quarters average, followed by Phase IV trials with an 11.0% share in Q3 2022, as against the four-quarter average of 11.1%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 50.7% share for non-industry sponsored clinical trials in Q3 2022, compared to 44.0% in the last four quarters.
Phase IV trials stood at second place with a 20.6% share in Q3 2022, compared to 22.6% in the last four quarters. Phase I trials held a 17.7% share in Q3 2022, as against 17.1% in the last four quarters, followed by Phase III trials with an 11.1% share in Q3 2022 over 16.4% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
